IP Library › Granted Patent US 12,252,477
Granted Patent B2
US 12,252,477 · App. 17/269,751 · Granted Mar 18, 2025

Applications of known and novel cannabinoids

Inventors: Barry A. Berkowitz (Framingham, MA); Anthony G. Barrett (Rio de Janeiro, BR); Daniel Elliott (Basel, CH)
Assignee: Bessor Pharma, LLC
C07D311/78A61K31/05A61K31/352C07C37/50C07C37/56C07C39/23C07D319/08C07D493/04C07C2601/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,252,477
App. No.
17/269,751
Granted
Mar 18, 2025
Kind
B2
Abstract

The use of a medicament as a single agent, binary agent, or other combination comprising of substantially pure novel cannabinoids 1 and 2, optionally admixed with one or more known and novel cannabinoids and other known naturally occurring and synthetic tetracyclic 2A and tricyclic 1A cannabinoids for the prevention, treatment or cure of inflammatory mediated diseases or inflammatory mediated pathological conditions, anorexia, arthritis, cancer, pain, glaucoma, migraine, persistent muscle spasms, seizures (epileptic seizures), severe nausea, PTSD, autism spectrum disorder, drug abuse, insomnia, or any other chronic or persistent medical symptom.

Claims (279)

1. A method of preventing, treating or curing an inflammatory mediated disease or inflammatory mediated pathological condition of one or more from the group consisting of the central or peripheral nervous system, cardiovascular-renal system, skin, gastrointestinal system, pulmonary-respiratory system, endocrine system, joints, musculo-skeletal system, blood or lymph system, genitourinary system, eye, and ear or for the prevention, treatment or cure of one or more of anorexia, arthritis, cancer, pain, glaucoma, migraine, persistent muscle spasms in an individual or animal in need of treatment and seizures, in an individual or animal in need of treatment comprising administering a medicament as single agent, binary agent, or other combination to the individual or animal, the medicament comprising

(a) one or more cannabinoids of the formulae 1 or 2;

(b) pharmaceutically acceptable excipients,

wherein formula 1 is:

wherein:

R B is selected from the group consisting of H or C 1 to C 2 alkyl, linear or branched C 3 to C 10 alkyl or double branched C 4 to C 10 alkyl, in each case optionally substituted by one or two hydroxyl groups or optionally substituted by one or more fluoro-groups, (CH 2 ) o —C 3 to C 6 cycloalkyl, (CH 2 ) p —OR F , and C 3 to C 6 cycloalkyl optionally substituted by a C 1 to C 8 alkyl;

o is an integer 0-6;

p is an integer 1-6; and

R 1 is selected from the group consisting of C 2 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H, CO 2 H and its pharmaceutically acceptable salts, CO 2 R C , CONHR D , and CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; and R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine; and

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl;

each r is independently an integer 0-6;

or wherein:

R 1 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of C 2 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H, CO 2 H and its pharmaceutically acceptable salts, CO 2 R C , CONHR D , and CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl or 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine; and

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently an integer 0-6;

or wherein:

R 1 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is CONHR D or CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently 0, 1, 2, 3, 4, 5 or 6;

and

wherein formula 2 is:

wherein:

R B is selected from the group consisting of H, C 1 to C 2 alkyl, linear or branched C 3 to C 10 alkyl and double branched C 4 to C 10 alkyl, in each case optionally substituted by one or two hydroxyl groups or optionally substituted by one or more fluoro-groups, (CH 2 ) o —C 3 to C 6 cycloalkyl, (CH 2 ) p —OR F , and C 3 to C 6 cycloalkyl optionally substituted by a C 1 to C 8 alkyl;

is an integer 0-6;

p is an integer 1-6; and

R 1 is selected from the group consisting of C 2 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H, CO 2 H and its pharmaceutically acceptable salts, CO 2 R C , CONHR D , and CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl or 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently an integer 0-6;

or wherein:

R 1 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of C 2 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H, CO 2 H and its pharmaceutically acceptable salts, CO 2 R C , CONHR D , and CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently an integer 0-6;

or wherein:

R 1 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or CH(CH 3 ) 2 ;

R A is CONHR D or CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl;

each r is independently an integer 0-6.

2. The method of claim 1 , wherein

the medicament comprises a compound of formula 1; and

R A is selected from the group consisting of H and CO 2 H and its pharmaceutically acceptable salts.

3. The method of claim 1 , wherein

the medicament comprises a compound of formula 1, wherein R A is selected from the group consisting of H and CO 2 H and pharmaceutically acceptable salts; and

R 1 is methyl.

4. The method of claim 1 , wherein

the medicament comprises a compound of formula 1, wherein

R A is selected from the group consisting of H and CO 2 H and its pharmaceutically acceptable salts;

R 2 is methyl.

5. The method of claim 1 , wherein the medicament comprises a compound of formula 1, wherein

R A is selected from the group consisting of H and CO 2 H and its pharmaceutically acceptable salts;

R 1 is methyl;

R 2 is methyl.

6. The method of claim 1 , wherein

the medicament comprises a compound of formula 2, wherein

R A is selected from the group consisting of H and CO 2 H and its pharmaceutically acceptable salts.

7. The method of claim 1 , wherein

the medicament comprises a compound of formula 2, wherein

R A is selected from the group consisting of H and CO 2 H and its pharmaceutically acceptable salts; and

R 1 is methyl.

8. The method of claim 1 , wherein

the medicament comprises a compound of formula 2, wherein

R A is selected from the group consisting of H and CO 2 H and its pharmaceutically acceptable salts; and

R 2 is methyl.

9. The method of claim 1 , wherein

the medicament comprises a compound of formula 2, wherein

R A is selected from the group consisting of H and CO 2 H and its pharmaceutically acceptable salts;

R 1 is methyl; and

R 2 is methyl.

10. The method of claim 1 , wherein

the medicament comprises a compound of formula 1 A :

wherein:

R 1 is selected from the group consisting of H, C 1 to Ce alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to Ce alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, (CH 2 ) m —OR 3 ,

each n is independently an integer selected from 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H and CO 2 H and its pharmaceutically acceptable salts;

R B is selected from the group consisting of H, C 1 to C 2 alkyl, linear or branched C 3 to C 10 alkyl, double branched C 4 to C 10 alkyl optionally substituted by one or two hydroxyl groups or one or more fluoro-groups, (CH 2 ) o —C 3 to C 6 cycloalkyl, (CH 2 ) p —OR F , C 3 to C 6 cycloalkyl optionally substituted by a C 1 to C 8 alkyl;

is an integer selected from 0-6:

p is an integer selected from 1-6;

R C is selected from C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer selected from 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently an integer selected from 0-6.

11. The method of claim 10 , wherein

R 1 is methyl.

12. The method of claim 11 , wherein

R 2 is methyl.

13. The method of claim 11 , wherein

R 1 is methyl; and

R 2 is methyl.

14. The method of claim 1 , wherein

the medicament comprises a compound of formula 2 B

wherein

R 1 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, (CH 2 ) m —OR 3 ;

each n is independently an integer selected from 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H and CO 2 H and its pharmaceutically acceptable salts;

R B is selected from the group consisting of H, C 1 to C 2 alkyl, linear or branched C 3 to C 10 alkyl, double branched C 4 to C 10 alkyl optionally substituted by one or two hydroxyl groups or one or more fluoro-groups, (CH 2 ) o —C 3 to C 6 cycloalkyl, (CH 2 ) p —OR F , C 3 to C 6 cycloalkyl optionally substituted by a C 1 to C 8 alkyl;

is an integer selected from 0-6;

p is an integer selected from 1-6;

R C is selected from C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer selected from 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently an integer selected from 0-6.

15. The method of claim 14 , wherein

R 1 is methyl.

16. The method of claim 14 , wherein

R 2 is methyl.

17. The method of claim 14 , wherein

R 1 is methyl; and

R 2 is methyl.

18. The method of claim 1 , wherein

the medicament comprises one or both of a compound of the formula 1 A and a compound of the formula 2 B :

selected from the group consisting of:

19. A method of preventing, treating or curing an affliction in an individual or animal that is treatable by affecting one or more from the group consisting of cannabinoid receptors, serotonin receptors, ion channels, Toll like receptors, opioid receptors, NMDA or excitatory amino acids receptors, catecholamine receptors enzymes regulating endocannabinoids comprising administering a medicament as single agent, binary agent, or other combination to the individual or animal, the medicament comprising

(a) one or more cannabinoids of the formulae 1 or 2; and

(b) pharmaceutically acceptable excipients,

wherein formula 1 is:

wherein:

R B is selected from the group consisting of H or C 1 to C 2 alkyl, linear or branched C 3 to C 10 alkyl or double branched C 4 to C 10 alkyl, in each case optionally substituted by one or two hydroxyl groups or optionally substituted by one or more fluoro-groups, (CH 2 ) o —C 3 to C 6 cycloalkyl, (CH 2 ) p —OR F , and C 3 to C 6 cycloalkyl optionally substituted by a C 1 to C 8 alkyl;

o is an integer 0-6;

p is an integer 1-6; and

R 1 is selected from the group consisting of C 2 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H, CO 2 H and its pharmaceutically acceptable salts, CO 2 R C , CONHR D , and CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; and R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine; and

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl;

each r is independently an integer 0-6;

or wherein:

R 1 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of C 2 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H, CO 2 H and its pharmaceutically acceptable salts, CO 2 R C , CONHR D , and CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine; and

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently an integer 0-6;

or wherein:

R 1 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is CONHR D or CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently 0, 1, 2, 3, 4, 5 or 6;

wherein formula 2 is:

wherein:

R B is selected from the group consisting of H, C 1 to C 2 alkyl, linear or branched C 3 to C 10 alkyl and double branched C 4 to C 10 alkyl, in each case optionally substituted by one or two hydroxyl groups or optionally substituted by one or more fluoro-groups, (CH 2 ) o —C 3 to C 6 cycloalkyl, (CH 2 ) p —OR F , and C 3 to C 6 cycloalkyl optionally substituted by a C 1 to C 8 alkyl;

is an integer 0-6;

p is an integer 1-6; and

R 1 is selected from the group consisting of C 2 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H, CO 2 H and its pharmaceutically acceptable salts, CO 2 R C , CONHR D , and CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently an integer 0-6;

or wherein:

R 1 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of C 2 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H, CO 2 H and its pharmaceutically acceptable salts, CO 2 R C , CONHR D , and CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, C 8 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently an integer 0-6;

or wherein:

R 1 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, and (CH 2 ) m —OR 3 ;

each n is independently an integer 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or CH(CH 3 ) 2 ;

R A is CONHR D or CONR D R E ;

R C is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 6 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently an integer 0-6.

20. The method of claim 1 , wherein the medicament comprises one or more cannabinoids of the formulae 1 A or 2 B :

wherein:

R 1 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, (CH 2 ) m —OR 3 ;

R 2 is selected from the group consisting of H, C 1 to C 6 alkyl, (CH 2 ) n —C 3 to C 6 cycloalkyl, (CH 2 ) m —OR 3 ;

each n is independently an integer selected from 0-2;

each m is independently 1 or 2;

R 3 is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ;

R A is selected from the group consisting of H, CO 2 H and pharmaceutically acceptable salts thereof, CO 2 R C , CONHR D and CONR D R E ;

R B is selected from the group consisting of H, C 1 to C 2 alkyl, linear or branched C 3 to C 10 alkyl, double branched C 4 to C 10 alkyl optionally substituted by one or two hydroxyl groups or one or more fluoro-groups, (CH 2 ) o —C 3 to C 6 cycloalkyl, (CH 2 ) p —OR F , C 3 to C 6 cycloalkyl optionally substituted by a C 1 to C 8 alkyl;

is an integer selected from 0-6;

p is an integer selected from 1-6;

R C is selected from C 1 to C 6 alkyl, (CH 2 ) q —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl;

q is an integer selected from 0-6;

R D is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; R E is C 1 to C 6 alkyl, (CH 2 ) r —C 3 to C 6 cycloalkyl, allyl, benzyl, substituted benzyl and 2-phenylethyl; or

NR D R E is selected from the group consisting of azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl, each optionally substituted by one or two hydroxyl groups or hydroxymethyl groups, with the proviso that the hydroxyl groups cannot be on the carbon bearing the heterocyclic ring nitrogen or the heterocyclic ring oxygen with morpholine;

R F is C 1 to C 8 alkyl or (CH 2 ) r —C 3 to C 6 cycloalkyl; and

each r is independently an integer selected from 0-6.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2021
From: BERKOWITZ, BARRY A.; BARRETT, ANTHONY G.; ELLIOTT, DANIEL
To: BESSOR PHARMA, LLC
Reel/Frame 055335/0357 →
Continuity (2)
Provisional Application 62719813 · Aug 20, 2018
Related Publication 20210236460A1 · Aug 5, 2021
References Cited (60)
US 6610737B1 · Garzon et al. · 2003 [cited by applicant]
US 6630507B1 · Hampson et al. · 2003 [cited by applicant]
US 7169942B2 · Moore, II et al. · 2007 [cited by applicant]
US 7759526B2 · Mechoulam et al. · 2010 [cited by applicant]
US 7906503B2 · Baker et al. · 2011 [cited by applicant]
US 8071641B2 · Weiss et al. · 2011 [cited by applicant]
US 8148404B2 · Cooper et al. · 2012 [cited by applicant]
US 8293786B2 · Stinchcomb et al. · 2012 [cited by applicant]
US 8410064B2 · Radominska-Pandya et al. · 2013 [cited by applicant]
US 9056866B2 · Adam et al. · 2015 [cited by applicant]
US 9139546B2 · Moore, II et al. · 2015 [cited by applicant]
US 9365534B2 · Mechoulam et al. · 2016 [cited by applicant]
US 9517989B2 · Makriyannis et al. · 2016 [cited by applicant]
US 9623000B2 · Kindler et al. · 2017 [cited by applicant]
US 10118892B2 · Arstad et al. · 2018 [cited by applicant]
US 10647691B2 · Erfurt et al. · 2020 [cited by applicant]
US 10807931B2 · Reekie et al. · 2020 [cited by applicant]
US 10844035B2 · Dialer et al. · 2020 [cited by applicant]
US 10898472B2 · Thorner · 2021 [cited by applicant]
US 11147776B2 · Stott et al. · 2021 [cited by applicant]
US 20070099987A1 · Weiss et al. · 2007 [cited by applicant]
US 20070213369A1 · Garzon et al. · 2007 [cited by applicant]
US 20090247619A1 · Stinchcomb et al. · 2009 [cited by applicant]
US 20090318526A1 · Weber et al. · 2009 [cited by applicant]
US 20170008868A1 · Dialer et al. · 2017 [cited by applicant]
US 20170008869A1 · Dialer et al. · 2017 [cited by applicant]
US 20170349518A1 · Dickman et al. · 2017 [cited by applicant]
US 20170362195A1 · Peet et al. · 2017 [cited by applicant]
US 20180325861A1 · Domb et al. · 2018 [cited by applicant]
US 20210163438A1 · Reekie et al. · 2021 [cited by applicant]
WO 2009099868A1 · 2009 [cited by applicant]
WO 2010054024A2 · 2010 [cited by applicant]
“2-(3-Ethyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)-5-pentylbenzene-1,3-diol, ”Compound Summary, PubChem CID 24201079. (Year: 2017). [cited by examiner]
“Cannabidiol, ”Compound Summary, PubChem CID644019 (Year: 2005). [cited by examiner]
Ermejo, Marival et al., “PAMPA—a drug absorption in vitro model 7.Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones, ”European Journal of Pharmaceutical Sciences, vol. 21, pp. 429-441. (Year: 200… [cited by examiner]
Arnold, William R. et al., “Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2,” J. Inorganic Biochemistry, vol. 184, p. 88-99 (2018). [cited by applicant]
Brown, N.K. et al., “In vivo metabolism of the n-butyl-homologues of Delta9-tetrahydrocannabinol and Delta8-tetrahydrocannabinol by the mouse,” Xenobiotica, vol. 18, No. 4, p. 417-427 (1988). [cited by applicant]
Brown, N.K. et al., “In vivo Metabolism of the Methyl Homologues of Delta-8-tetrahydrocannabinol, Delta-9-tetrahydrocannabinol and abn-Delta-8-tetrahydrocannabinol in the Mouse,” Biomedical and Environmental Mass Spectr… [cited by applicant]
Fride, Ester et al., “Peripheral, but not central effects of cannabidiol derivatives: Mediation by CB1 and unidentified receptors,” Neuropharmacology, vol. 48, No. 8, p. 1117-1129 (2005). [cited by applicant]
Hanus, Lumir O. et al., “Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors,” Organic & Biomolecular Chemistry, vol. 3, No. 6, p. 1116-1123 (2005). [cited by applicant]
Harvey, D.J. et al., “In Vitro Metabolism of Cannabidiol in Seven Common Laboratory Mammals,” Research Communications in Substances of Abuse, vol. 11, Nos. 1 & 2, p. 27-37 (1990). [cited by applicant]
Harvey, D.J. et al., “In vitro Metabolism of Cannabidiol in the Rabbit: Identification of Seventeen New Metabolites Including Thirteen Dihydroxylated in the Isopropenyl Chain,” Biomedical and Environmental Mass Spectrom… [cited by applicant]
Harvey, D.J. et al., “Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography—mass spectrometry,” J. Chromatography, vol. 562, No. 1-2, p. 299-322 (1991). [cited by applicant]
Jung, Julia et al., “Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques,” J. Mass Spectrome… [cited by applicant]
Razdan, R.K. et al., “(-)-8Beta-Hydroxymethyl-Delta1-Tetrahydrocannabinol: A Novel Physiologically Active of Delta1-Tetrahydrocannabinol,” Experientia, vol. 32, No. 4, p. 416-417 (1976). [cited by applicant]
Siegel, Craig et al., “Synthesis of Racemic and Optically Active Delta9-Tetrahydrocannabinol (THC) Metabolites,” J. Organic Chemistry, vol. 56, p. 6865-6872 (1991). [cited by applicant]
Silva, Tania B.E. et al., “Study of the Structure-Activity Relationship for Theoretical Molecular Descriptors Using Density Functional Theory and Chemometric Methods in Cannabinoid Metabolites,” International J. Quantum… [cited by applicant]
International Search Report and Written Opinion mailed Dec. 27, 2019 for International Patent Application No. PCT/US2019/047284. [cited by applicant]
“2-[(1R,6R)-3-Methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol,” Compound Summary, PubChem CID 57933486, Aug. 19, 2012. [cited by applicant]
“2-(3-Ethyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)-5-pentylbenzene-1,3-diol,” Compound Summary, PubChem CID 124201079, Feb. 18, 2017. [cited by applicant]
“Cannabidiol,” Compound Summary, PubChem CID 644019, Jun. 8, 2005. [cited by applicant]
“Methyl 3-[(1S,6S)-6-ethenyl-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxy-6-pentylbenzoate,” Compound Summary, PubChem CID 126581859, Apr. 22, 2017. [cited by applicant]
Bermejo, Marival et al., “PAMPA-a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones,” European Journal of Pharmaceutical Sciences, vol. 21, pp. 429-441 (2004). [cited by applicant]
Ahmed, Safwat A. et al., “Cannabinoid Ester Constituents from High-Potency Cannabis sativa,” J. Nat. Prod., 71, p. 536-542, 2008. [cited by applicant]
Rosenthaler, Sarah et al., “Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures,” Neurotoxicology and Teratology, 46, p. 49-56, 2014. [cited by applicant]
Brookes, Paul A. et al., “Total Synthesis of Mycophenolic Acid by a Palladium-Catalyzed Decarboxylative Allylation and Biomimetic Aromatization Sequence,” Eur. J. Org. Chem., 32, p. 7313-7319, 2013. [cited by applicant]
Elliott, Daniel C. et al., “Sequential Ketene Generation from Dioxane-4,6-dione-keto-dioxinones for the Synthesis of Terpenoid Resorcylates,” Organic Letters, 18, p. 1800-1803, 2016. [cited by applicant]
Hanus, Lumir O. et al., “Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors,” Org. Biomol. Chem., 3, p. 1116-1123, 2005. [cited by applicant]
Ma, Tsz-Kan et al., “Meroterpenoid total synthesis: Conversion of geraniol and farnesol into amorphastilbol, grifolin and grifolic acid by dioxinone-β-keto-acylation, palladium catalyzed decarboxylative allylic rearrang… [cited by applicant]
Martin, Billy R., “Structural Requirements for Cannabinoid-Induced Antinociceptive Activity in Mice,” Life Sciences, vol. 36, p. 1523-1530, 1985. [cited by applicant]